Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch and national availability of its ATN Profile, a blood-based test that combines three, well-researched blood biomarkers to identify and assess biological changes associated with Alzheimer's disease .
Test is available through physicians for use with patients being evaluated for possible Alzheimer s disease or other causes of cognitive impairment
Labcorp is the first company to deliver a.
Labcorp on Wednesday began marketing to U.S. physicians the first test for a trio of blood biomarkers it says can detect the hallmarks of Alzheimer's, accelerating diagnosis of the brain-wasting disease and potentially helping patients access treatment. Labcorp's Amyloid-Tau-Neurodegeneration (ATN) Profile is not precise enough to definitively diagnose Alzheimer's, but offers a convenient way for doctors to determine which patients need advanced testing, said Brian Caveney, Labcorp’s chief medical and scientific officer. Patients with a positive ATN test would still need a CSF test or PET scan to confirm an Alzheimer's diagnosis.
Global life science giant Labcorp is rolling out a test that it says can speed up a diagnosis for Alzheimer's and thus lead to earlier intervention to fight the deadly disease.
Health News Roundup: Labcorp launches 3-part blood test for Alzheimer s; GSK settles another California lawsuit on heartburn drug Zantac and more devdiscourse.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from devdiscourse.com Daily Mail and Mail on Sunday newspapers.